secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-069818
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Q1 cash $65.1M; pivots (Z)-endoxifen to metastatic breast cancer
-----------------------------------------------------------------------

- Ended Q1 2025 with $65.1M cash, no debt; no revenue reported.
- Strategic shift to metastatic breast cancer as lead indication for (Z)-endoxifen.
- Added 3 new US patents, expanding IP portfolio to over 200 claims related to (Z)-endoxifen.
- Operating expenses $7.4M (up $0.4M YoY) with R&D $4.2M, G&A $3.3M.
- Interest income $0.7M, down from $1.1M due to lower money market balance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025069818/0000950170-25-069818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025069818/atos-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer